GENMAB A/S -SP ADR
GMAB · NASDAQ
Updated at 2026-10-14 10:14:06
- Today's High
- $37.35
- Today’s Low
- $36.34
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $37.18
- Previous Close
- $37.37
- Volume
- 3.12M
- Market Cap
- $146.13B
- P/E Ratio
- 27.73X
- EPS
- $12.69
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- CARL JACOBSENS VEJ 30, COPENHAGEN, DENMARK, 2500
- Country
- DK
- Listing Date
- 2000-10-01
- Fiscal Year End
- December
- Shares Outstanding
- 62.35M
- CIK
- 0001434265
- Website
- www.genmab.com
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Financial Metrics
Revenue
2026-06-30
$1.15B
2026-03-31
$899.31M
2025-12-31
$1.05B
2025-09-30
$1.02B
Operating Expenses
2026-06-30
$664M
2026-03-31
$608.24M
2025-12-31
$731.78M
2025-09-30
$505M
Net Income
2026-06-30
$303M
2026-03-31
$53.19M
2025-12-31
$30.9M
2025-09-30
$401M
Net Profit Margin
2026-06-30
26.23%
2026-03-31
5.91%
2025-12-31
2.93%
2025-09-30
39.23%
Earnings Per Share
2026-06-30
$0.54
2026-03-31
$0.13
2025-12-31
$0.21
2025-09-30
$0.65
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
$431M
2026-03-31
$186.68M
2025-12-31
$98.7M
2025-09-30
$503M
Effective Tax Rate
2026-06-30
-2.71%
2026-03-31
28.37%
2025-12-31
43.63%
2025-09-30
16.8%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $1.15B | $899.31M | $1.05B | $1.02B |
| Operating Expenses | $664M | $608.24M | $731.78M | $505M |
| Net Income | $303M | $53.19M | $30.9M | $401M |
| Net Profit Margin | 26.23% | 5.91% | 2.93% | 39.23% |
| Earnings Per Share | $0.54 | $0.13 | $0.21 | $0.65 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | $431M | $186.68M | $98.7M | $503M |
| Effective Tax Rate | -2.71% | 28.37% | 43.63% | 16.8% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.